News in English
Scandibio, whose board includes prominent Swedish scientists such as Mathias Uhlén and Henrik Zetterberg, has developed a drug candidate now being clinically tested in Alzheimer’s patients with mild, moderate, and severe symptoms. The treatment aims to boost the mitochondria—the cells’ powerhouses—in the brain, thereby improving memory. A Phase III trial has begun in Turkey with the goal of enrolling 600 patients.
Swedish drug development projects in Phase III – studies to keep an eye on
Developing new medicines is, as we know, a lengthy and uncertain process, and only a fraction of all projects ever reach late clinical phase. But it does happen – and here we highlight a number of promising Swedish drug candidates currently in Phase III that are worth watching more closely.
Annons
BREAKING